SAR 31.95
(2.4%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 407.73 Million SAR | 11.08% |
2022 | 367.07 Million SAR | 20.55% |
2021 | 304.49 Million SAR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 209.39 Million SAR | 2.84% |
2023 Q2 | 204.13 Million SAR | 4.54% |
2023 Q4 | 203.6 Million SAR | -0.26% |
2023 FY | 407.74 Million SAR | 11.08% |
2022 Q2 | 171.8 Million SAR | 0.0% |
2022 FY | 367.07 Million SAR | 20.55% |
2022 Q4 | 195.27 Million SAR | 13.66% |
2021 FY | 304.49 Million SAR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 338.43 Million SAR | -20.476% |
Al-Dawaa Medical Services Company | 5.74 Billion SAR | 92.898% |
Nahdi Medical Company | 8.71 Billion SAR | 95.321% |
Al-Razi Medical Co. | 61.33 Million SAR | -564.787% |